What if the mosquito net
wasn’t completely closed?

Japanese Encephalitis (JE) is a potentially severe disease – but can be preventable^2,3

A traveller to any of 24 countries in Asia can be infected with Japanese Encephalitis (JE) virus. In rare cases, JE viral infection can result in encephalitis.^4,5

Learn more about helping to protect travellers from Japanese Encephalitis

What is JE?

Help Reduce Risk for Your Patients by Knowing the Facts

CLICK TO EXPAND

KEY FACTS ABOUT JAPANESE ENCEPHALITIS

Japanese Encephalitis is not just in Japan

The Japanese Encephalitis virus is endemic to 24 countries across Asia and Southeast Asia, as well as parts of the western Pacific.⁴

JE occurs across Asia

Over 70,000 symptomatic cases of JE are estimated to occur each year in Asia.⁴
It is not possible to predict who will develop the disease – the majority of infections in humans are asymptomatic; clinical disease develops in one in every 50 to 1,000 individuals infected.¹

JE is the most common vaccine-
preventable encephalitis in Asia

JE is the leading cause of viral-induced neurologic sequelae.^4,6

Up to 30% who develop JE die, and up
to 50% of JE survivors suffer long-term
sequelae^4*

*Neurologic, cognitive, and psychiatric sequelae^4,6

There is no specific
treatment for JE

The only protection against JE is prevention^6,7†

† IXIARO® is not indicated to prevent consequences of JE once it develops.

CLICK TO EXPAND

KEY FACTS ABOUT JAPANESE ENCEPHALITIS

Japanese Encephalitis is not just in Japan

The Japanese Encephalitis virus is endemic to 24 countries across Asia and Southeast Asia, as well as parts of the western Pacific.⁴

JE occurs across Asia

Over 70,000 symptomatic cases of JE are estimated to occur each year in Asia⁴
It is not possible to predict who will develop the disease – the majority of infections in humans are asymptomatic; clinical disease develops in one in every 50 to 1,000 individuals infected.¹

JE is the most common vaccine
-preventable encephalitis in Asia

JE is the leading cause of viral-induced neurologic sequelae.^4,6

Up to 30% who develop JE die, and up
to 50% of JE survivors suffer long-term
sequelae^4*

*Neurologic, cognitive, and psychiatric sequelae^4,6

There is no specific
treatment for JE

The only protection against JE is prevention^6,7†

† IXIARO® is not indicated to prevent consequences of JE once it develops.

One vaccine can help
protect them

Consider IXIARO® for your patients aged
≥ 2 months for the prevention of JE¹

What can you do to help protect
patients against JE?

Learn more about risk reduction strategies
and vaccination for travellers at risk

What is IXIARO?®

Learn More

Help prevent JE

Learn More

One vaccine can help
protect them

Consider IXIARO® for your patients aged
≥ 2 months for the prevention of JE¹

What is Ixiaro?®

Learn More

What can you do to help protect
patients against JE?

Learn more about risk reduction strategies
and vaccination for travellers at risk

Help prevent JE

Learn More

IXIARO® is indicated for active immunization against Japanese Encephalitis for persons 2 months of age and older.

IXIARO® should be considered for use in individuals at risk of exposure through travel or in the course of their occupation. As with any other vaccine, vaccination with IXIARO® may not result in protection in all cases. IXIARO® will not protect against encephalitis caused by other micro-organisms.

Check the Safety Information section for additional information discussing

Contraindications: Hypersensitivity to this vaccine or to any ingredient in the formulation or component of the container; do not give the second dose to individuals who show hypersensitivity reactions after the first dose; postpone vaccination with IXIARO® in persons with acute severe febrile conditions
Most serious warnings and precautions regarding treating rare cases of anaphylactic reactions following the administration of the vaccine; administration of IXIARO® and bleeding disorders
Other relevant warnings and precautions regarding pregnant and nursing women, geriatrics (≥65 years of age) and immunosuppressed individuals
Conditions of clinical use, adverse reactions, drug interactions and dosing instructions

Please see IXIARO® Product Monograph for complete prescribing information.

Important Safety Information | References

What is Japanese Encephalitis?

Help prevent Japanese Encephalitis

What is IXIARO®?

Contact Valneva

Terms of Use

Privacy Policy

VALNEVA Canada Inc.
600-3535, Saint-Charles Blvd.
Kirkland (Montreal), Quebec
H9H 5B9

Cookie	Duration	Description
cookielawinfo-checkbox-analytics	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional	11 months	The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy	11 months	The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.

Country	Affected areas	Transmission season
Australia	Outer Torres Strait Islands, parts of four states on mainland (New South Wales, Queensland, South Australia, Victoria)	December–May
Bangladesh	Widespread	Year-round with most cases reported July–November
Bhutan	Presumed widespread in nonmountainous areas	Unknown
Brunei Darussalam	Presumed widespread	Unknown
Burma (Myanmar)	Widespread	Year-round with most cases reported May–September
Cambodia	Widespread	Year-round; peak season May–October
China	All provinces except Xinjiang and Qinghai	Peak season June–October
India	Andhra Pradesh, Arunachal Pradesh, Assam, Bihar, Goa, Haryana, Jharkhand, Karnataka, Kerala, Maharashtra, Manipur, Meghalaya, Nagaland, Odisha, Punjab, Tamil Nadu, Telangana, Tripura, Uttar Pradesh, Uttarakhand, West Bengal	Peak season May–November, especially in northern India; the season may be extended or yearround in some areas, especially in southern India
Indonesia	Widespread	Year-round, with peak season varying by island
Japan	All islands	June–October
Lao People’s Democratic Republic	Widespread	Year-round; peak season June–September
Malaysia	Widespread	Year-round, with peak season in Sarawak from October–December
Nepal	Southern lowlands (Terai), some hill and mountain districts	Peak season June–October
North Korea	Presumed widespread	Unknown Proximity to South Korea suggests peak transmission May–November
Pakistan	Unknown	Unknown
Papua New Guinea	Widespread	Presumed year-round
Philippines	Widespread	Year-round; peak season April–August
Russia	Primorsky Krai	June–September
Singapore	Presumed in focal areas	Year-round
Sri Lanka	Widespread except in mountainous areas	Year-round with peak season November–February
Taiwan	Widespread	Peak season May–October
Thailand	Widespread	Year-round with peak season May–October, especially in northern Thailand Highest rates of disease reported from Chiang Mai Valley Several traveler cases reported in recent years from resort and coastal areas of southern Thailand
Timor-Leste	Presumed widespread	No data Proximity to West Timor suggests year-round
Viet Nam	Widespread	Year-round with peak season May–October, especially in northern Viet Nam
† Destination and transmissions season information should be considered in association with travel duration and activities when making decisions on vaccination.²²
‡ Data are based on published and unpublished reports. Risk assessments should be performed cautiously, because risk can vary within areas and from year to year, and surveillance data regarding human cases and JE virus transmission are often incomplete. In some endemic areas, human cases among residents are limited because of vaccination or natural immunity among older people. However, because JE virus is maintained in an enzootic cycle between animals and mosquitoes, susceptible visitors to these areas still may be at risk for infection.²²
§ Outbreaks previously occurred in the Western Pacific Islands of Guam (1947–1948) and Saipan (1990), but as they are no longer considered risk areas, they are not included in the table.²²

What if the mosquito net
wasn’t completely closed?

What if the mosquito net
wasn’t completely closed?

Japanese Encephalitis (JE) is a potentially severe disease – but can be preventable^2,3

Help Reduce Risk for Your Patients by Knowing the Facts

KEY FACTS ABOUT JAPANESE ENCEPHALITIS

Japanese Encephalitis is not just in Japan

JE occurs across Asia

JE is the most common vaccine-
preventable encephalitis in Asia

Up to 30% who develop JE die, and up
to 50% of JE survivors suffer long-term
sequelae^4*

There is no specific
treatment for JE

KEY FACTS ABOUT JAPANESE ENCEPHALITIS

Japanese Encephalitis is not just in Japan

JE occurs across Asia

JE is the most common vaccine
-preventable encephalitis in Asia

Up to 30% who develop JE die, and up
to 50% of JE survivors suffer long-term
sequelae^4*

There is no specific
treatment for JE

One vaccine can help
protect them

What can you do to help protect
patients against JE?

What is IXIARO?®

Help prevent JE

One vaccine can help
protect them

What is Ixiaro?®

What can you do to help protect
patients against JE?

Help prevent JE

Myth: Travellers are only bitten during the rainy season

Myth: JE only occurs in travellers staying 30 days or more in endemic countries

Myth: Risk for JE virus transmission only exists in rural areas

Myth: Temporal and spatial distribution of JE can be predicted

JE Checklist for Travel to Asia
When to consider IXIARO®

Keep in mind the 3 O’s

JE Checklist for Travel to Asia
When to consider IXIARO®

Keep in mind the 3 O’s

What if the mosquito netwasn’t completely closed?

What if the mosquito netwasn’t completely closed?

Japanese Encephalitis (JE) is a potentially severe disease – but can be preventable2,3

Help Reduce Risk for Your Patients by Knowing the Facts

KEY FACTS ABOUT JAPANESE ENCEPHALITIS

Japanese Encephalitis is not just in Japan

JE occurs across Asia

JE is the most common vaccine- preventable encephalitis in Asia

Up to 30% who develop JE die, and up to 50% of JE survivors suffer long-term sequelae4*

There is no specific treatment for JE

KEY FACTS ABOUT JAPANESE ENCEPHALITIS

Japanese Encephalitis is not just in Japan

JE occurs across Asia

JE is the most common vaccine -preventable encephalitis in Asia

Up to 30% who develop JE die, and up to 50% of JE survivors suffer long-term sequelae4*

There is no specific treatment for JE

One vaccine can helpprotect them

What can you do to help protectpatients against JE?

What is IXIARO?®

Help prevent JE

One vaccine can helpprotect them

What is Ixiaro?®

What can you do to help protectpatients against JE?

Help prevent JE

What if the mosquito net
wasn’t completely closed?

What if the mosquito net
wasn’t completely closed?

Japanese Encephalitis (JE) is a potentially severe disease – but can be preventable^2,3

JE is the most common vaccine-
preventable encephalitis in Asia

Up to 30% who develop JE die, and up
to 50% of JE survivors suffer long-term
sequelae^4*

There is no specific
treatment for JE

JE is the most common vaccine
-preventable encephalitis in Asia

Up to 30% who develop JE die, and up
to 50% of JE survivors suffer long-term
sequelae^4*

There is no specific
treatment for JE

One vaccine can help
protect them

What can you do to help protect
patients against JE?

One vaccine can help
protect them

What can you do to help protect
patients against JE?